Troglitazone

AdipoGen Life Sciences
Product Code: AG-CR1-3565
Product Group: Other Biochemicals
CodeSizePrice
AG-CR1-3565-M0055 mg£65.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; Romglizone; BRN 4338399; CS-045; CI-991; GR 92132X
Appearance:
White to off-white solid.
CAS:
97322-87-7
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light.
InChi:
InChi=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)
InChiKey:
GXPHKUHSUJUWKP-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 97322-87-7. Formula: C24H27NO5S. MW: 441.5. Potent and selective PPARgamma agonist with no activation of PPARalpha and PPARdelta. Anti-diabetic agent with potent glucose-lowering effects and decreasing insulin resistance in adipose tissues. Stimulates adipogenesis. Apoptosis and cell cycle arrest inducer in several cancer cell lines. Anti-inflammatory. Inhibits vascular smooth muscle cell (VSMC) migration.
MDL:
MFCD00878416
Molecular Formula:
C24H27NO5S
Molecular Weight:
441.5
Package Type:
Vial
Product Description:
Potent and selective PPARgamma agonist with no activation of PPARalpha and PPARdelta [2]. Anti-diabetic agent with potent glucose-lowering effects and decreasing insulin resistance in adipose tissues. Stimulates adipogenesis [1, 6, 8]. Apoptosis and cell cycle arrest inducer in several cancer cell lines [3-8]. Anti-inflammatory [8-10, 12]. Inhibits vascular smooth muscle cell (VSMC) migration [11].
Purity:
>98%
SMILES:
CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O
Solubility Chemicals:
Soluble in DMSO, ethanol or dimethylformamide (DMF).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats: T. Fujiwara, et al.; Diabetes 37, 1549 (1988) | An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995) | Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids: H. Asou, et al.; Int. J. Oncol. 15, 1027 (1999) | Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators: Y. Kodera, et al.; J. Biol. Chem. 275, 33201 (2000) | Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis: Y. Tsubouchi, et al.; BBRC 270, 400 (2000) | Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000) | Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells: T. Okura, et al.; Eur. J. Pharmacol. 407, 227 (2000) | Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000) (Review) | Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese: H. Ghanim, et al.; J. Clin. Endocrinol. Metab. 86, 1306 (2001) | Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: A. Aljada, et al.; evidence of an antiinflammatory action?: J. Clin. Endocrinol. Metab. 86, 3250 (2001) | Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration: S. Goetze, et al.; J. Cardiovasc. Pharmacol. 38, 909 (2001) | Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300: K. Subbaramaiah, et al.; J. Biol. Chem. 276, 12440 (2001)

Related Products

Product NameProduct CodeSupplier 
CiglitazoneAG-CR1-0033AdipoGen Life Sciences Summary Details
PioglitazoneAG-CR1-0067AdipoGen Life Sciences Summary Details
RosiglitazoneAG-CR1-3570AdipoGen Life Sciences Summary Details
Rosiglitazone . maleateAG-CR1-3571AdipoGen Life Sciences Summary Details